M42, AstraZeneca, and SOPHiA GENETICS have announced a new initiative to enhance cancer diagnosis and care in the United Arab Emirates through advanced liquid biopsy testing. This strategic collaboration aims to improve the accuracy of cancer diagnoses, inform treatment decisions, and facilitate real-time monitoring of disease progression in a manner that is both cost-effective and...
